These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 17516560)

  • 1. Network analysis of FDA approved drugs and their targets.
    Ma'ayan A; Jenkins SL; Goldfarb J; Iyengar R
    Mt Sinai J Med; 2007 Apr; 74(1):27-32. PubMed ID: 17516560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Network-based drug ranking and repositioning with respect to DrugBank therapeutic categories.
    Re M; Valentini G
    IEEE/ACM Trans Comput Biol Bioinform; 2013; 10(6):1359-71. PubMed ID: 24407295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-target network.
    Yildirim MA; Goh KI; Cusick ME; Barabási AL; Vidal M
    Nat Biotechnol; 2007 Oct; 25(10):1119-26. PubMed ID: 17921997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative analysis on the characteristics of targets with FDA approved drugs.
    Sakharkar MK; Li P; Zhong Z; Sakharkar KR
    Int J Biol Sci; 2007 Dec; 4(1):15-22. PubMed ID: 18167532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview of the FDA publication Approved Drug Products with Therapeutic Equivalence Evaluations.
    Knoben JE; Scott GR; Tonelli RJ
    Am J Hosp Pharm; 1990 Dec; 47(12):2696-700. PubMed ID: 2278285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updates on drug-target network; facilitating polypharmacology and data integration by growth of DrugBank database.
    Barneh F; Jafari M; Mirzaie M
    Brief Bioinform; 2016 Nov; 17(6):1070-1080. PubMed ID: 26490381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective.
    Li YH; Wang PP; Li XX; Yu CY; Yang H; Zhou J; Xue WW; Tan J; Zhu F
    PLoS One; 2016; 11(11):e0165737. PubMed ID: 27828998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of U.S. Food and Drug Administration-Approved Antibiotics, 2010-2015.
    Deak D; Outterson K; Powers JH; Kesselheim AS
    Ann Intern Med; 2016 Sep; 165(5):363-72. PubMed ID: 27239977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-drug associations: a complex system.
    Dalkic E; Wang X; Wright N; Chan C
    PLoS One; 2010 Apr; 5(4):e10031. PubMed ID: 20368808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs.
    Ladanie A; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
    Trials; 2018 Sep; 19(1):505. PubMed ID: 30231912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Examination of risk evaluation and mitigation strategies and drug safety in the US.
    Rodriguez-Monguio R; Spielberger K; Seoane-Vazquez E
    Res Social Adm Pharm; 2014; 10(1):232-8. PubMed ID: 23611865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in the exploitation of novel drug targets.
    Rask-Andersen M; Almén MS; Schiöth HB
    Nat Rev Drug Discov; 2011 Aug; 10(8):579-90. PubMed ID: 21804595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repurposing FDA-approved drugs for anti-aging therapies.
    Snell TW; Johnston RK; Srinivasan B; Zhou H; Gao M; Skolnick J
    Biogerontology; 2016 Nov; 17(5-6):907-920. PubMed ID: 27484416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Network Analysis of Drug-target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015.
    Lin HH; Zhang LL; Yan R; Lu JJ; Hu Y
    Sci Rep; 2017 Sep; 7(1):12230. PubMed ID: 28947756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.
    Sacks LV; Shamsuddin HH; Yasinskaya YI; Bouri K; Lanthier ML; Sherman RE
    JAMA; 2014 Jan 22-29; 311(4):378-84. PubMed ID: 24449316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals.
    Hao J; Rodriguez-Monguio R; Seoane-Vazquez E
    PLoS One; 2015; 10(10):e0140708. PubMed ID: 26469277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic analysis of FDA-approved anticancer drugs.
    Sun J; Wei Q; Zhou Y; Wang J; Liu Q; Xu H
    BMC Syst Biol; 2017 Oct; 11(Suppl 5):87. PubMed ID: 28984210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using DrugBank for In Silico Drug Exploration and Discovery.
    Wishart DS; Wu A
    Curr Protoc Bioinformatics; 2016 Jun; 54():14.4.1-14.4.31. PubMed ID: 27322405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How safe are recently FDA-approved antimicrobials? A review of the FDA adverse event reporting system database.
    Khadem TM; van Manen RP; Brown J
    Pharmacotherapy; 2014 Dec; 34(12):1324-9. PubMed ID: 25421400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.